Kidney outcome after mild to moderate COVID-19.

Autor:	Schmidt-Lauber C; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hänzelmann S; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schunk S; Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University, Homburg/Saar, Germany., Petersen EL; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany., Alabdo A; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Lindenmeyer M; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hausmann F; Institute of Medical Systems Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kuta P; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Renné T; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.; Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany., Twerenbold R; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany.; University Center of Cardiovascular Science, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck., Zeller T; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany.; University Center of Cardiovascular Science, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck., Blankenberg S; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck., Fliser D; Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University, Homburg/Saar, Germany., Huber TB; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jazyk:	angličtina
Zdroj:	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Aug 31; Vol. 38 (9), pp. 2031-2040.
DOI:	10.1093/ndt/gfad008
Abstrakt:	Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela. Methods: This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria. Results: A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)]. Conclusion: While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela. (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu